Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 465

Results For "company"

4865 News Found

Kilitch starts injectables production at Ethiopia
News | July 27, 2021

Kilitch starts injectables production at Ethiopia

The Cephalosporin Injectables plant has a total capacity of 26.4 million vials per year while Ethiopia is having a demand for 16 million vials


Alembic Pharmaceuticals Q1FY22 net slides to Rs. 164.52 Cr
News | July 27, 2021

Alembic Pharmaceuticals Q1FY22 net slides to Rs. 164.52 Cr

The US business faced price erosion due to increased competition.


Biocon Biologics partners Adagio to manufacture antibody for COVID-19
News | July 27, 2021

Biocon Biologics partners Adagio to manufacture antibody for COVID-19

ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses


Glenmark Life Sciences IPO to open on July 27, 2021
News | July 26, 2021

Glenmark Life Sciences IPO to open on July 27, 2021

The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration


Panacea Biotec posts consolidated loss of Rs. 57.35 Cr in Q1FY22
News | July 26, 2021

Panacea Biotec posts consolidated loss of Rs. 57.35 Cr in Q1FY22

It posted net (loss) of Rs.(34.13) crores for the period ended June 30, 2020.


Lonza reports strong momentum in H1 2021
News | July 24, 2021

Lonza reports strong momentum in H1 2021

The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth


Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr
News | July 23, 2021

Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr

Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).


Gland Pharma Q1FY22 consolidated PAT rises to Rs. 350.65 Cr
News | July 22, 2021

Gland Pharma Q1FY22 consolidated PAT rises to Rs. 350.65 Cr

The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.


Syngene Q1 FY22 revenue grows 41%
News | July 21, 2021

Syngene Q1 FY22 revenue grows 41%

The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels


EMA grants ODD to Saroglitazar Mg
News | July 21, 2021

EMA grants ODD to Saroglitazar Mg

Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC